And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. We hope to catch up on some reading, hang with a short person or two, and promenade with the official mascot. We will also stop to observe some ancient, but meaningful, rituals. And what about you? This is a fine time to consider a little spring cleaning, or enjoy the great outdoors. You could putter around your castle or try to make that appointment for a vaccine. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …
Novavax (NVAX) is delaying signing a contract to supply its Covid-19 vaccine to the European Union because the company is struggling to source some raw materials, according to Reuters. Prolonging the talks with the EU might further complicate vaccination plans, as the bloc had planned to sign a deal early this year for at least 100 million doses of the vaccine, with an option for another 100 million. Novavax has eight manufacturing locations, including the Serum Institute of India, the world’s biggest vaccine maker.
With its own battle against the coronavirus taking a sharp turn for the worse, India has severely curtailed exports of Covid-19 vaccines, triggering setbacks for vaccination drives in many other countries, The New York Times explains. The Indian government is now holding back nearly all of the 2.4 million doses that the Serum Institute of India, a private company that is one of the world’s largest producers of the AstraZeneca (AZN) vaccine, makes each day. Just a few weeks ago, India was a major exporter of the AstraZeneca vaccine.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect